CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"> <head> <meta charset="utf-8" /> <script async src="https://www.googletagmanager.com/gtag/js?id=G-273DTKB5QW"></script> <meta name="description" content="FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER)" /> <meta name="dcterms.title" content="FDA Drug Safety Podcasts" /> <meta name="dcterms.creator" content="Center for Drug Evaluation and Research" /> <meta name="dcterms.description" content="FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER)" /> <meta name="dcterms.publisher" content="FDA" /> <meta name="dcterms.source" content="FDA" /> <meta property="og:site_name" content="U.S. Food and Drug Administration" /> <meta property="og:type" content="Article" /> <meta property="og:url" content="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-podcasts" /> <meta property="og:title" content="FDA Drug Safety Podcasts" /> <meta property="og:description" content="FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER)" /> <meta property="og:image" content="https://www.fda.gov/files/DrugSafetyPodcast-iTunesAlbumGraphic_3000x3000-min.png" /> <meta property="og:updated_time" content="Fri, 09/20/2024 - 00:00" /> <meta property="article:published_time" content="Tue, 09/24/2024 - 08:28" /> <meta property="article:modified_time" content="Fri, 09/20/2024 - 00:00" /> <meta name="google-site-verification" content="tWxlDhm4ANdksJZPj7TBmHgNoMqZCnecPp0Aa2vC9XA" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@US_FDA" /> <meta property="twitter:description" content="FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER)" /> <meta name="twitter:title" content="FDA Drug Safety Podcasts" /> <meta name="twitter:creator" content="@US_FDA" /> <meta name="twitter:image" content="https://www.fda.gov/files/DrugSafetyPodcast-iTunesAlbumGraphic_3000x3000-min.png" /> <meta name="MobileOptimized" content="width" /> <meta name="HandheldFriendly" content="true" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <script type="application/ld+json">{ "@context": "https://schema.org", "@graph": [ { "@type": "Article", "headline": "FDA Drug Safety Podcasts", "name": "FDA Drug Safety Podcasts", "description": "FDA Drug Safety Podcasts are produced by FDA\u0027s Center for Drug Evaluation and Research (CDER)", "image": { "@type": "ImageObject", "representativeOfPage": "True", "url": "https://www.fda.gov/files/DrugSafetyPodcast-iTunesAlbumGraphic_3000x3000-min.png" }, "datePublished": "Tue, 09/24/2024 - 08:28", "dateModified": "Fri, 09/20/2024 - 00:00", "author": { "@type": "Organization", "name": "Center for Drug Evaluation and Research" }, "publisher": { "@type": "Organization", "name": "FDA" } } ] }</script> <link rel="icon" href="/themes/custom/preview/favicon.ico" type="image/vnd.microsoft.icon" /> <link rel="alternate" hreflang="en" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-podcasts" /> <link rel="canonical" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-podcasts" /> <link rel="shortlink" href="https://www.fda.gov/node/359990" /> <script src="/files/google_tag/production/google_tag.script.js?smjbjq" defer></script> <title>FDA Drug Safety Podcasts | FDA</title> <link rel="stylesheet" media="all" href="/files/css/css_9imYfj47K1t2vTOWSq90pbKkayA7se1ZmOedZ20axik.css?delta=0&language=en&theme=preview&include=eJxlT9GOwjAM-6GO3stJ_E2VtVmpaOuqyYHG17OB2IBTpMiyldieUJWuLChspx0fTARiZkeV8qzJi_0mjMyiXOxIwqZ1viS-2pgxUh5E55xq_Ef7npqKGQEV7dRsQ8OFu5kCOX_mkBTdcT1R9Vy4qljyHj0kVKeIawA5oatH2E2X4yGQLjNmlg_69fNdX0Wxj30oCH-Zn_YoLafV-Km535_jG2mmJXSFstgNbVa-023muBcO1D4ibqGHrc8deO2Utg" /> <link rel="stylesheet" media="all" href="/files/css/css_xLeUZALg1CD0YmiSIzZnqkwKfNF_g3TkAjkxBt_uccA.css?delta=1&language=en&theme=preview&include=eJxlT9GOwjAM-6GO3stJ_E2VtVmpaOuqyYHG17OB2IBTpMiyldieUJWuLChspx0fTARiZkeV8qzJi_0mjMyiXOxIwqZ1viS-2pgxUh5E55xq_Ef7npqKGQEV7dRsQ8OFu5kCOX_mkBTdcT1R9Vy4qljyHj0kVKeIawA5oatH2E2X4yGQLjNmlg_69fNdX0Wxj30oCH-Zn_YoLafV-Km535_jG2mmJXSFstgNbVa-023muBcO1D4ibqGHrc8deO2Utg" /> <script src="https://script.crazyegg.com/pages/scripts/0024/3700.js" async></script> <script src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&subagency=FDA&sdor=fda.gov&dclink=true" language="javascript" id="_fed_an_ua_tag"></script> <script>window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag("js", new Date());gtag("set", "developer_id.dMDhkMT", true);gtag("config", "G-273DTKB5QW", {"groups":"default","page_placeholder":"PLACEHOLDER_page_location","allow_ad_personalization_signals":false});</script> </head> <body class="role-anonymous path-node page-node-type-sub-section has-glyphicons"> <div id="quicklinks" class="sr-only"> <ul> <li><a href="#main-content" class="sr-only sr-only-focusable" tabindex="1">Skip to main content</a></li> <li><a href="#search-form" class="sr-only sr-only-focusable" tabindex="1">Skip to FDA Search</a></li> <li><a href="#section-nav" class="sr-only sr-only-focusable" tabindex="1">Skip to in this section menu</a></li> <li><a href="#footer-heading" class="sr-only sr-only-focusable" tabindex="1">Skip to footer links</a></li> </ul> </div> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M95XGZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas> <div class="main-container container-fluid"> <div class="row"> <header class="lcds-header container-fluid" role="heading" aria-level="1"> <div class="row us-masthead"> <div class="usa-banner col-xs-12"> <img class="usa-banner__us-flag" src="/themes/custom/preview/assets/images/US_Flag.png" alt="U.S. flag" /> <span>An official website of the United States government</span> <a id="USMenuButton" class="collapsed" data-toggle="collapse" data-target="#USABannerMenu" aria-controls="USABannerMenu">Here’s how you know <span class="toggle-indicator"> </span></a> <div class="col-xs-12 collapse usa-banner__menu" id="USABannerMenu" aria-labelledby="USMenuButton"> <div id="gov-banner" class="row usa-banner-content usa-grid usa-accordion-content" aria-hidden="true"> <div class="col-xs-12 col-sm-6 col-md-3"> <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-dot-gov.svg" alt="Dot gov" style="width:3em;"> <div class="usa-media_block-body"> <p><strong>The .gov means it’s official.</strong><br>Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.</p> </div> </div> <div class="col-xs-12 col-sm-6 col-md-3"> <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-https.svg" alt="SSL" style="width:3em;"> <div class="usa-media_block-body"> <p><strong>The site is secure.</strong><br> The <strong>https://</strong> ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.</p> </div> </div> </div> </div> </div> </div> <div class="alert alert-warning margin-left-neg-2 margin-right-neg-2 margin-top-3 margin-bottom-1"> <p>On Oct. 1, 2024, the FDA began implementing a <a href="/about-fda/fda-organization/fda-modernization-efforts-establishing-unified-human-foods-program-new-model-field-operations-and" title="FDA Modernization Efforts for Establishing a Unified Human Foods Program, New Model for Field Operations and More">reorganization</a> impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.</p> </div> <div class="row fda-masthead"> <div class="col-xs-4 col-md-8"> <a href="/" title="FDA Homepage"> <h1 class="fda-masthead__fda-logo">U.S. Food and Drug Administration</h1> </a> </div> <div class="col-xs-8 col-md-4"> <ul class='fda-masthead__item-list'> <li><a title="" id="btn-search" class="btn btn-default btn-sm fda-masthead__btn-search"> <span class="fa fa-search" aria-hidden="true"> </span> <span class="fda-masthead__btn-label">Search</span> </a></li> <li><a id="menu-btn" class="btn btn-default btn-sm fda-masthead__btn-menu collapsed" href="#primary-nav" data-toggle="collapse" aria-expanded="true"> <span class="fa fa-bars" aria-hidden="true"> </span> <span class='fda-masthead__btn-label'>Menu</span> </a></li> </ul> </div> <form class="fda-masthead__search sr-only" role="search" action="/search" method="GET" name="searchForm" id="search-form" accept-charset="UTF-8" > <div class="search-popover" id="search-popover"> <div class="input-group pull-right" id="search-group"> <label class="sr-only" for="search-query">Search FDA</label> <input class="form-control search-input" id="search-query" name="s" aria-autocomplete="list" aria-haspopup="true" title="Enter the terms you wish to search for." placeholder="Search FDA" type="text" /> <span class="input-group-btn" id="input-group-btn"> <button type="submit" class="btn btn-danger search-btn" id="search-btn" title="Search"><span class="fa fa-search" aria-hidden="true"><span class="sr-only">Submit search</span></span></button> </span> </div> </div> </form> </div> <nav id="primary-nav" class="lcds-primary-nav row collapse"> <div class="col-md-5 col-lg-4"> <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered"> <h2 class="lcds-primary-nav__group-heading">Featured</h2> <ul class="lcds-primary-nav__list lcds-primary-nav__list--featured"> <li class="lcds-primary-nav__list-item"><a href="https://www.safetyreporting.hhs.gov/smarthub#/" title="Report a Problem with an FDA Regulated Product">Report a Product Problem</a></li> <li class="lcds-primary-nav__list-item"><a href="/about-fda/contact-fda">Contact FDA</a></li> <li class="lcds-primary-nav__list-item"><a href="/regulatory-information/search-fda-guidance-documents">FDA Guidance Documents</a></li> <li class="lcds-primary-nav__list-item"><a href="/safety/recalls-market-withdrawals-safety-alerts">Recalls, Market Withdrawals and Safety Alerts</a></li> <li class="lcds-primary-nav__list-item"><a href="/news-events/newsroom/press-announcements">Press Announcements</a></li> <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a></li> <li class="lcds-primary-nav__list-item"><a href="/advisory-committees">Advisory Committees</a></li> <li class="lcds-primary-nav__list-item"><a href="/fda-en-espanol">En Espa&#241ol</a></li> </ul> </section> </div> <div class="col-md-7 col-lg-8"> <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered"> <h2 class="lcds-primary-nav__group-heading">Products</h2> <ul class="lcds-primary-nav__list"> <li class="lcds-primary-nav__list-item"><a href="/food">Food</a></li> <li class="lcds-primary-nav__list-item"><a href="/drugs">Drugs</a></li> <li class="lcds-primary-nav__list-item"><a href="/medical-devices">Medical Devices</a></li> <li class="lcds-primary-nav__list-item"><a href="/radiation-emitting-products">Radiation-Emitting Products</a></li> <li class="lcds-primary-nav__list-item"><a href="/vaccines-blood-biologics">Vaccines, Blood, and Biologics</a></li> <li class="lcds-primary-nav__list-item"><a href="/animal-veterinary">Animal and Veterinary</a></li> <li class="lcds-primary-nav__list-item"><a href="/cosmetics">Cosmetics</a></li> <li class="lcds-primary-nav__list-item"><a href="/tobacco-products">Tobacco Products</a></li> </ul> </section> <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered"> <h2 class="lcds-primary-nav__group-heading">Topics</h2> <ul class="lcds-primary-nav__list"> <li class="lcds-primary-nav__list-item"><a href="/about-fda">About FDA</a></li> <li class="lcds-primary-nav__list-item"><a href="/combination-products">Combination Products</a></li> <li class="lcds-primary-nav__list-item"><a href="/regulatory-information">Regulatory Information</a></li> <li class="lcds-primary-nav__list-item"><a href="/safety">Safety</a></li> <li class="lcds-primary-nav__list-item"><a href="/emergency-preparedness-and-response">Emergency Preparedness</a></li> <li class="lcds-primary-nav__list-item"><a href="/international-programs">International Programs</a></li> <li class="lcds-primary-nav__list-item"><a href="/news-events">News and Events</a></li> <li class="lcds-primary-nav__list-item"><a href="/training-and-continuing-education">Training and Continuing Education</a></li> <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections and Compliance</a></li> <li class="lcds-primary-nav__list-item"><a href="/science-research">Science and Research</a></li> </ul> </section> <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered"> <h2 class="lcds-primary-nav__group-heading">Information For</h2> <ul class="lcds-primary-nav__list"> <li class="lcds-primary-nav__list-item"><a href="/consumers">Consumers</a></li> <li class="lcds-primary-nav__list-item"><a href="/patients">Patients</a></li> <li class="lcds-primary-nav__list-item"><a href="/industry">Industry</a></li> <li class="lcds-primary-nav__list-item"><a href="/health-professionals">Health Professionals</a></li> <li class="lcds-primary-nav__list-item"><a href="/federal-state-local-tribal-and-territorial-officials">Federal, State and Local Officials</a></li> </ul> </section> </div> </nav> </header> <div class="col-xs-12"> <div data-drupal-messages-fallback class="hidden"></div> </div> <section id="block-entityviewcontent" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> <a class="lcds-button--expandable collapsed hidden-md hidden-lg" data-toggle="collapse" href="#section-nav">In this section<span class="visible-sm-inline-block">: Drug Safety and Availability </span> </a> <nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav hidden-md hidden-lg collapse"> <ul class="lcds-section-nav__list"> <li> <a href="/drugs/drug-safety-and-availability/fda-drug-safety-podcasts" class="lcds-section-nav__section-link lcds-section-nav__link lcds-section-nav__parent-link">FDA Drug Safety Podcasts</a> <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_5 js-view-dom-id-bdc7381c1135464eaf3b02fe97705b46af40b6c2845569c2d6b8631c49bb41dc"> </div> </div> <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_2 js-view-dom-id-e545e5aa9ed4fb1033b0c0015ee3a10cabdc45238975108be38e2cda444a89d7"> </div> </div> </li> </ul> </nav> </section> <section id="block-entityviewcontent-15" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> <ol class="lcds-breadcrumb visible-md visible-lg"> <li > <a href="/">Home</a> </li> <li > <a href="/drugs">Drugs</a> </li> <li > <a href="/drugs/drug-safety-and-availability">Drug Safety and Availability</a> </li> <li > <a class="current-link">FDA Drug Safety Podcasts</a> </li> </ol> <ol class="lcds-breadcrumb visible-sm visible-xs"> <li> <a href="/drugs/drug-safety-and-availability" title="Drug Safety and Availability"> Drug Safety and Availability </a> </li> </ol> </section> <main> <article id="main-content" class="article main-content container-fluid" role="article"> <header class="row content-header" role="heading" aria-level="1"> <section id="block-entityviewcontent-14" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> <div class="col-sm-12 col-md-8 col-md-offset-2"> <h1 class="content-title text-center">FDA Drug Safety Podcasts</h1> <div class="lcds-toolbar lcds-toolbar--social"> <ul class="lcds-share lcds-share--default"> <li class="lcds-share__item"> <a href="https://www.facebook.com/sharer/sharer.php?u=https://www.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-podcasts" class="lcds-share__btn lcds-share--default__btn-facebook js-share" id="fb-share" target="_blank"><span class="fa icon-facebook" aria-hidden="true"></span>Share</a> </li> <li class="lcds-share__item"> <a href="https://x.com/intent/tweet/?text=FDA%20Drug%20Safety%20Podcasts&url=https://www.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-podcasts" target="_blank" class="lcds-share__btn lcds-share--default__btn-x-twitter js-share" id="twitter-share"> <svg class="icon-svg-inline" aria-hidden="true"> <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter"> </svg> Post </a> </li> <li class="lcds-share__item hidden-xs"> <a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-podcasts&title=FDA%20Drug%20Safety%20Podcasts&source=FDA" class="lcds-share__btn lcds-share--default__btn-linkedin js-share" id="linkedin-share" target="_blank"><span class="fa icon-linkedin" aria-hidden="true"></span>Linkedin</a> </li> <li class="lcds-share__item"> <a href="mailto:?subject=FDA%20Drug%20Safety%20Podcasts&body=https://www.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-podcasts" class="lcds-share__btn lcds-share--default__btn-mail"><span class="fa icon-envelope" aria-hidden="true"></span>Email</a> </li> <li class=" lcds-share__item hidden-xs"> <a href="javascript:window.print();" title="Print this page" class="lcds-share__btn lcds-share--default__btn-print"><span class="fa icon-print" aria-hidden="true"></span>Print</a> </li> </ul> <div class="form-group"> </div> </div> </div> </section> </header> <div class="col-md-8 col-md-push-2" role="main"> <div alt="FDA Drug Safety Podcast Graphic " data-embed-button="media_browser" data-entity-embed-display="media_image" data-entity-embed-display-settings="Array" data-entity-type="media" data-entity-uuid="3b38faba-c3dc-4620-a9f5-a39590ad32b6" data-langcode="en" title="FDA Drug Safety Podcast Graphic " class="align-left embedded-entity"> <img loading="lazy" src="/files/DDI_DrugSafetyPodcast_SocialMedia_900x900_unbranded_240717.png" alt="FDA Drug Safety Podcast Graphic " title="FDA Drug Safety Podcast Graphic " class="img-responsive"> </div> <p><br> The FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER). They provide emerging safety information about drugs in conjunction with the release of <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a0521673-c69e-4f4e-ba3d-3b78057ff103" href="/drugs/drug-safety-and-availability/drug-safety-communications" title="Drug Safety Communications">Drug Safety Communications</a>.</p> <p><a href="https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drug-safety-podcast/rss.xml">RSS feed for FDA Drug Safety Podcasts</a></p> <hr> <div type="warning"> <div class="alert alert-warning"> <div class=" panel-group" id="accordion_323686" role="tablist" aria-multiselectable="true"> <div title="Continuing Education Credits (CE) Instructions" open="no" class=" panel panel-default fda-accordion-panel"> <div class="panel-heading" role="tab" id="heading_67462fbb4bb89"> <h2 class="panel-title"> <a role="button" class="collapsed" data-toggle="collapse" data-parent href="#67462fbb4bb89" aria-controls="67462fbb4bb89">Continuing Education Credits (CE) Instructions</a> </h2> </div> <div id="67462fbb4bb89" class="panel-collapse collapse collapsed" role="tabpanel" aria-labelledby="heading_67462fbb4bb89"> <div class="panel-body"> <h3>Login, complete evaluation, and print certificate</h3> <ol> <li>Navigate to <a href="https://ceportal.fda.gov/">ceportal.fda.gov</a></li> <li>If you have an account, please login</li> <li>If you do not have an account, click on “Create an account!”</li> <li>Once you’re logged in, please complete your profile if you haven't done so already</li> <li>Navigate to the “Enduring Materials” tab</li> <li>Select the activity you want to complete</li> <li>Click on the “Enroll” button. As you complete all the steps listed in the box, a green checkmark will appear</li> <li>Begin the activity by clicking on the link at the bottom of the page</li> <li>After listening to the podcast, click on “Complete Post-test”</li> <li>After successful completion of the Post-test, click on “Complete Evaluation”</li> <li>After completion of the evaluation, you may view/print your statement of credit and/or certificate of completion</li> </ol> <h3>Requirements for receiving CE credits</h3> <p>Review the activity, complete the post-test and evaluation. Upon completion, learners may view or print their statement of credit.</p> <p>For those of you who are pharmacists or pharmacy technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy—otherwise known as “NABP”—provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor.  If you do not see your credit reflected on the CPE Monitor after 45 days after completion of the activity, please contact <a href="mailto:FDACETeam@fda.hhs.gov">FDACETeam@fda.hhs.gov</a>. The CPE Monitor sets a strict 60-day limit on uploading credits.</p> </div> </div> </div> </div> <p><strong>Claim 0.5 CE credit (CME/AAPA/CNE/CPE/CPT/CPH) by listening to our podcast and responding to the questions</strong></p> </div> </div> <hr> <div class="row"> <div class=" col-sm-12 col-md-4 col-lg-4"> <p><span contenteditable="false" tabindex="-1"><a class="no-disclaimer" data-widget="image" href="https://podcasts.apple.com/us/podcast/fda-drug-safety-podcasts/id1556505073" target="_blank"><img alt="Listen on Apple Podcasts" src="/media/155035/download" title="Listen on Apple Podcasts"></a></span></p> </div> <div class=" col-sm-12 col-md-4 col-lg-4"> <p><span contenteditable="false" tabindex="-1"><a class="no-disclaimer" data-widget="image" href="https://music.youtube.com/playlist?list=PLey4Qe-UxcxZUgTcrNL3CR3WOcdHRs0T2" target="_blank"><img alt="Listen on YouTube Podcasts" src="/media/177930/download" title="Listen on YouTube Podcasts"></a></span></p> </div> <div class=" col-sm-12 col-md-4 col-lg-4"> <p><span contenteditable="false" tabindex="-1"><a class="no-disclaimer" data-widget="image" href="https://open.spotify.com/show/0TAxDirUJW8cbaSCiXzban?si=GCVcFFClSDyF2A5ca4nPvQ&nd=1" target="_blank"><img alt="Listen on Spotify Podcasts" src="/media/155037/download" title="Listen on Spotify Podcasts"></a></span></p> </div> </div> <div class="lcds-datatable lcds-datatable--ckeditor"> <table class="table table-striped" data-excel-button="true" data-order="[ 2, "desc" ]" data-paging="true" data-searching="true" summary="Drug Safety Podcasts"> <thead> <tr> <th scope="col">Title</th> <th scope="col">CE</th> <th scope="col">Date</th> <th scope="col">Podcast</th> <th scope="col">Transcript</th> </tr> </thead> <tbody> <tr> <td>FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause</td> <td>No</td> <td data-order="20240920">September 20, 2024</td> <td><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="a49d6901-6d54-4698-81b3-964f993e63c8" href="/media/181957/download?attachment" title="Podcast for DSCVeozah09122024">Listen</a><br> Run Time:<br> 00:3:30</td> <td><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="caa59466-93f5-4a51-8a58-a7e715aaeb27" href="/drugs/fda-drug-safety-podcasts/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due" title="FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause">Transcript</a></td> </tr> <tr> <td>FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)</td> <td>Yes</td> <td data-order="20240119">January 19, 2024</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/175986/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:4:00</td> <td><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="991a1441-6020-4986-9c3b-7bf12a6e57a4" href="/drugs/fda-drug-safety-podcasts/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease" title="FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)">Transcript</a></td> </tr> <tr> <td>Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity</td> <td>Yes</td> <td data-order="20240111">January 11, 2024</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/175709/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:3:30</td> <td><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d51e237f-1c7a-4a5f-9d9c-f8ecb1d96a51" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type" title="Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity">Transcript</a></td> </tr> <tr> <td>FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)</td> <td>Yes</td> <td data-order="20231128">November 28, 2023</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/174539/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:5:05</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="afced502-0750-4c1b-8994-199e5e5c1687" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr" title="FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)">Transcript</a></span></td> </tr> <tr> <td>FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions</td> <td>Yes</td> <td data-order="20230511">May 11, 2023</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/168520/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:5:30</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a6e648d8-c017-4aae-9353-833ad108a137" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions" title="FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions">Transcript</a></span></td> </tr> <tr> <td>FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use</td> <td>Yes</td> <td data-order="20230413">April 13, 2023</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/167997/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:7:30</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f7715cd4-440f-471f-8290-4fc80c37b704" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" title="FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use">Transcript</a></span></td> </tr> <tr> <td>FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)</td> <td>No</td> <td data-order="20221122">November 22, 2022</td> <td> <p><span id="cke_bm_357S" style="display: none;"> </span><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/163985/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:4:00</p> </td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b2797358-a2f5-4eb1-bb5b-bac63a72e823" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-investigating-risk-severe-hypocalcemia-patients-dialysis-receiving-osteoporosis-medicine-prolia" title="FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)">Transcript</a></span></td> </tr> <tr> <td>FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)</td> <td>No</td> <td data-order="20220630">June 30, 2022</td> <td> <p><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/160303/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:4:00</p> </td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0148a412-d06f-4447-af1d-b8816e9b857b" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra" title="FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)">Transcript</a></span></td> </tr> <tr> <td>FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns</td> <td>No</td> <td data-order="20220601">June 1, 2022</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/159674/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:2:00</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="30a5eaa5-58e8-488a-aae7-8a23942e131c" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-withdrew-its-approval-cancer-medicine-ukoniq-umbralisib-due-safety-concerns" title="FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns">Transcript</a></span></td> </tr> <tr> <td>FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging</td> <td>No</td> <td data-order="20220330">March 30, 2022</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-widget="btbutton" href="/media/157621/download"><span class="Listen">Listen</span></a></span><br> Run Time:<br> 00:4:30</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b51dd4db-8093-4017-86cc-20fbb1f9877f" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-recommends-thyroid-monitoring-babies-and-young-children-who-receive-injections-iodine-containing" title="FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)</td> <td>No</td> <td data-order="20220203">February 3, 2022</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="8ff378f2-5c6e-4ce0-9e93-1d898e9c6b2f" data-widget="btbutton" href="/media/156025/download?attachment" title="Drug Safety Podcast for Ukoniq"><span class="text">Listen</span></a></span><br> Run Time:<br> 00:3:30</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e24d9e0f-a05c-4d42-8a79-3ab7569de362" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-investigating-possible-increased-risk-death-lymphoma-medicine-ukoniq-umbralisib" title="FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain</td> <td>No</td> <td data-order="20220112">January 12, 2022</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="ef84414f-0900-41d7-8df0-d8fea5403cbc" data-widget="btbutton" href="/media/155519/download?attachment" title="Podcast for Drug Safety Communication Buprenorphine, January 12, 2022"><span class="text">Listen</span></a></span><br> Run Time:<br> 00:5:59</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0b2ab875-04a2-440a-a1d1-9f9a097cfb9d" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder" title=" FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury</td> <td>No</td> <td data-order="20211102">November 2, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="5e54d29b-9ead-41b9-ab5a-ce1af4f37ff0" data-widget="btbutton" href="/media/153948/download?attachment" title="Podcast for Alcohol based Hand sanitizer DSC, November 2, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:4:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1cc6f8e6-7f98-400c-b24d-1ae639b696af" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-getting-alcohol-based-hand-sanitizer-eyes-can-cause-serious-injury" title="FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions</td> <td>No</td> <td data-order="20210901">September 1, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="07b97f31-2d56-4085-b740-77286ea8af3e" data-widget="btbutton" href="/media/152033/download?attachment" title="Drug Safety Podcast for JAKinhibitorsDSC, September 1, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:4:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="87a32de6-711e-4b19-9881-779e81509146" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death" title="FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins</td> <td>No</td> <td data-order="20210720">July 20, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="57376a32-7bb4-4ce4-93b7-c4733af03f1a" data-widget="btbutton" href="/media/151000/download?attachment" title="Podcast for StatinsDSC, July 20, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="cc2fa923-ea8f-4536-a359-d269db1ef381" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy" title="FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns that vapors from alcohol-based hand sanitizers can have side effects</td> <td>No</td> <td data-order="20210616">June 16, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="54078a68-393e-4f42-adbb-7c46835b4fa3" data-widget="btbutton" href="/media/150189/download?attachment" title="Drug Safety Podcast for Hand Sanitizers, June 16, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:4:29</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3ec24c46-3448-4861-be33-9d896a34f55d" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-vapors-alcohol-based-hand-sanitizers-can-have-side-effects" title="FDA warns that vapors from alcohol-based hand sanitizers can have side effects"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis</td> <td>No</td> <td data-order="20210526">May 26, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="376d4466-180e-4e7e-8ffb-36b3e091ef9e" data-widget="btbutton" href="/media/149675/download?attachment" title="Podcast for Ocaliva, May 26, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:38</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="050d84da-92ca-4635-8b32-7befe8724b50" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/due-risk-serious-liver-injury-fda-restricts-use-obeticholic-acid-ocaliva-primary-biliary-cholangitis" title="Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease</td> <td>No</td> <td data-order="20210331">March 31, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="8ddb0d46-b489-4b97-815b-52f888dc6f5e" data-widget="btbutton" href="/media/147282/download?attachment" title="Drug Safety Podcast for Lamotrigine, March 31, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d6ebb991-e5a4-4e6e-b754-45c9d8d73c0e" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/studies-show-increased-risk-heart-rhythm-problems-seizure-and-mental-health-medicine-lamotrigine" title="Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns that abuse and misuse of the OTC nasal decongestant propylhexedrine can lead to serious harm</td> <td>No</td> <td data-order="20210325">March 25, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="3117935c-b0af-4f28-8b7d-9845c7aae6f1" data-widget="btbutton" href="/media/147149/download?attachment" title="Drug Safety Podcast for Propylhexedrine, March 25, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="aa2a78f1-5a0c-4377-bc80-303cfd0ae74b" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-abuse-and-misuse-otc-nasal-decongestant-propylhexedrine-can-lead-serious-harm" title="FDA warns that abuse and misuse of the OTC nasal decongestant propylhexedrine can lead to serious harm"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)</td> <td>No</td> <td data-order="20210204">February 4, 2021</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="ff3c2ee4-b8f6-424f-a4dc-ee9e3e904e6e" data-widget="btbutton" href="/media/145714/download?attachment" title="Drug Safety Podcast for Tofacitinib, February 4, 2021"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6951cf66-ba29-4c51-b9a0-3b559342bbf3" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis" title="Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid</td> <td>No</td> <td data-order="20201015">October 15, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="d7aa0739-69eb-4456-aedc-d4063d4cd90c" data-widget="btbutton" href="/media/143073/download?attachment" title="Drug Safety Podcast for NSAIDs in pregnancy"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="55efd486-2464-4457-a684-0b12fbd0dced" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" title="FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)</td> <td>No</td> <td data-order="20200924">September 24, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="3f41ca06-ce04-434a-aa14-22c2d96741cf" data-widget="btbutton" href="/media/142491/download?attachment" title="Drug Safety Podcast for Diphenhydramine (Benadryl)"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5a4acbc0-bc57-4e78-bb96-68bfdffbcc55" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-serious-problems-high-doses-allergy-medicine-diphenhydramine-benadryl" title="FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class</td> <td>No</td> <td data-order="20200923">September 23, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="458e19cd-57e1-49d2-9268-9117ea42f370" data-widget="btbutton" href="/media/142499/download?attachment" title="Drug Safety Podcast for Benzodiazepines"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="afbef156-d368-42e1-a669-b27fd4e1eb37" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class" title="FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)</td> <td>No</td> <td data-order="20200826">August 26, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="708b1651-e068-43e7-9dd7-bbc8339874f5" data-widget="btbutton" href="/media/141731/download?attachment" title="Drug Safety Podcast Canagliflozin"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:2:59</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6086c840-449a-46a5-97e9-6e8090970748" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin" title="FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder</td> <td>No</td> <td data-order="20200723">July 23, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="f56b6096-88bd-4770-bd2f-48512ac58586" data-widget="btbutton" href="/media/140605/download?attachment" title="Drug Safety Podcast for Naloxone July 23, 2020"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:31</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3915358d-4bda-45a8-acad-81bdf87c2238" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain" title="FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder "><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems</td> <td>No</td> <td data-order="20200424">April 24, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="5764885c-48d6-483c-89a5-81cf05ce8186" data-widget="btbutton" href="/media/137343/download?attachment" title="Drug Safety Podcast for Chloroquine_hydroxychloroquineDSC_04242020"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:32</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a938144f-bf19-4ef9-8628-b2c76e6cedb7" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or" title="FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis</td> <td>No</td> <td data-order="20200304">March 4, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="2b5aa3be-2524-411b-81cd-f0f66630f1b3" data-widget="btbutton" href="/media/135983/download?attachment" title="Drug Safety Podcast Montelukast"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="7bc213f5-f6ea-4263-aae9-5311a4b80f5f" data-widget="btbutton" href="/drugs/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug" title="FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market</td> <td>No</td> <td data-order="20200213">February 13, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="89efe907-609b-40d2-88dd-84d9c6146cb4" data-widget="btbutton" href="/media/135330/download?attachment" title="Drug Safety Podcast Belviq"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b284af45-86e5-47be-80ee-dd331d5ecb8d" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market" title="FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems</td> <td>No</td> <td data-order="20200128">January 28, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="f87cd25f-3417-473c-9683-a9db9b8d0494" data-widget="btbutton" href="/media/135041/download?attachment" title="Drug Safety Podcast Clozapine Janaury 28, 2020"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8d7e905c-4ec8-4c1c-8ee1-7189545f4690" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-strengthens-warning-untreated-constipation-caused-schizophrenia-medicine-clozapine-clozaril-can" title="FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)</td> <td>No</td> <td data-order="20200114">January 14, 2020</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="f6653bae-f7ca-4e0c-a140-fa6a4fcd90c3" data-widget="btbutton" href="/media/134501/download?attachment" title="Drug Safety Podcast Lorcaserin"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:2:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="22b2a40b-8c3e-4ea1-8753-bbc9668f8efb" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr" title="Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)</td> <td>No</td> <td data-order="20191219">December 19, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="bf4850dd-9dcc-4350-8c04-ed329f23e638" data-widget="btbutton" href="/media/133881/download?attachment" title="Drug Safety Podcast Gabapentinoids December 2019"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="73d78a35-6d78-4911-8f81-aa6b540aa2ed" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin" title="FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer</td> <td>No</td> <td data-order="20190913">September 13, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="44477628-8978-418b-9bf2-a22aa2ac1902" data-widget="btbutton" href="/media/131003/download?attachment" title="Drug Safety Podcast for CDK 4-6 Inhibitors"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ed5ac282-70a4-4b83-82ea-51e20c796513" data-widget="btbutton" href="/drugs/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer" title="FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease</td> <td>No</td> <td data-order="20190828">August 28, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="beca1dd7-a171-4b50-956a-6bdaf762d00b" data-widget="btbutton" href="/media/130669/download?attachment" target title="Drug Safety Podcast for Hepatitis C Meds"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="681b3a48-bcd8-4c6c-9b24-85fb2d3c6b91" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and" title="FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)</td> <td>No</td> <td data-order="20190813">August 13, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="7ffcc1b9-a462-4a16-bb0c-95bac620cbc9" data-widget="btbutton" href="/media/130168/download?attachment" target title="Drug Safety Podcast Stalevo "><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5b474a27-4b3f-43a0-99e1-852f532f5cee" data-widget="btbutton" href="/drugs/fda-review-finds-no-increased-risk-prostate-cancer-parkinsons-disease-medicines-containing" title="FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)</td> <td>No</td> <td data-order="20190726">July 26, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="ace76777-12e6-48c4-9502-48a8224980ea" data-widget="btbutton" href="/media/129647/download?attachment" target title="Drug Safety PodcastTofacitinibUpdate"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="aebab68d-c6dc-4055-be83-e86db9bda9de" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and" title="FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines</td> <td>No</td> <td data-order="20190430">April 30, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="6734b7bd-60c5-4ce2-bb16-f064385dcebb" data-widget="btbutton" href="/media/124881/download?attachment" target title="Drug Safety Podcast for Z-Drugs"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a9895418-a893-4993-9ed7-d036d9c1c1c2" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia" title="FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering</td> <td>No</td> <td data-order="20190409">April 9, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="66fb1d6c-0e73-4ee5-847b-84a754d1a600" data-widget="btbutton" href="/media/123270/download?attachment" target title="Drug Safety Podcast Opioid Tapering "><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c7b657e2-49c2-46dc-8278-a0f0e171cc0c" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes" title="FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate</td> <td>No</td> <td data-order="20190225">February 25, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="befe705a-1db3-45c1-9522-6d15af17d340" data-widget="btbutton" href="/media/120796/download?attachment" target title="Drug Safety Podcast for Tofacitinib (Xeljanz, Xeljanz XR)"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="20b19a5e-7eb5-4cef-a46a-0c6d912e2923" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr" title="Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)</td> <td>No</td> <td data-order="20190221">February 21, 2019</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/120591/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="dfbc6038-71d5-43a1-adce-8d38882d6fc0" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat" title="FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)</td> <td>No</td> <td data-order="20181129">November 29, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="d8f67af6-211d-4739-8f2d-b135fa3053ad" data-widget="btbutton" href="/media/120795/download?attachment" target title="Drug Safety Podcast for Idhifa (enasidenib)"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="dd0bcd02-d0ef-4313-b028-1ccdcc85f1ad" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-symptoms-serious-condition-affecting-blood-cells-are-not-being-recognized-leukemia" title="FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)</td> <td>No</td> <td data-order="20181129">November 29, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="media_download" data-entity-type="media" data-entity-uuid="d9d83091-621d-4dc0-89c7-bca1165cb260" data-widget="btbutton" href="/media/120794/download?attachment" target title="Drug Safety Podcast for Lemtrada"><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c1c6c070-2c84-435b-bb3a-3173d6ec47c3" data-widget="btbutton" href="/drugs/fda-drug-safety-podcasts/fda-warns-about-rare-serious-risks-stroke-and-blood-vessel-wall-tears-multiple-sclerosis-drug" title="FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)</td> <td>No</td> <td data-order="20181120">November 20, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/118427/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5ddb0cbb-7317-4f6d-b0a1-795b6659146b" data-widget="btbutton" href="/drugs/fda-warns-about-severe-worsening-multiple-sclerosis-after-stopping-medicine-gilenya-fingolimod" title="FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod)"><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes</td> <td>No</td> <td data-order="20180829">August 29, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/115613/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant</td> <td>No</td> <td data-order="20180803">August 3, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/115273/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about-increased-risk-cancer-relapse-long-term-use-azithromycin" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes</td> <td>No</td> <td data-order="20180710">July 10, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/114747/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics</td> <td>No</td> <td data-order="20180518">May 23, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/113987/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-risk-serious-and-potentially-fatal-blood-disorder-prompts-fda-action-oral" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)</td> <td>No</td> <td data-order="20180518">May 18, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/113545/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:30</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-evaluate-potential-risk-neural-tube-birth-defects-hiv-medicine" target><span class="text">Transcript</span> </a></span></td> </tr> <tr> <td>FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)</td> <td>No</td> <td data-order="20180425">April 25, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/112799/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-serious-immune-system-reaction-seizure-and-mental-health-medicine" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease</td> <td>No</td> <td data-order="20180222">February 22, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/111303/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:2:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-review-finds-additional-data-supports-potential-increased-long-term" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease</td> <td>No</td> <td data-order="20180201">February 1, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/111259/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-adds-boxed-warning-highlight-correct-dosing-ocaliva-obeticholic-acid" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use</td> <td>No</td> <td data-order="20180130">January 30, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/111183/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-limits-packaging-anti-diarrhea-medicine-loperamide-imodium-encourage" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older</td> <td>No</td> <td data-order="20180111">January 11, 2018</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/110284/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:09</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-requires-labeling-changes-prescription-opioid-cough-and-cold-medicines" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS) </td> <td>No</td> <td data-order="20171220">December 20, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/110007/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes-long" target><span class="text">Transcript</span> </a></span></td> </tr> <tr> <td>FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings</td> <td>No</td> <td data-order="20171219">December 19, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/109512/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body-requires" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)</td> <td>No</td> <td data-order="20171115">November 15, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/109177/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-evaluate-increased-risk-heart-related-death-and-death-all-causes-gout" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease</td> <td>No</td> <td data-order="20170921">September 21, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/108051/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about-serious-liver-injury-ocaliva-obeticholic-acid-rare-chronic" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks</td> <td>No</td> <td data-order="20170920">September 20, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/107645/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:30</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-urges-caution-about-withholding-opioid-addiction-medications-patients" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs</td> <td>No</td> <td data-order="20170906">September 6, 2017 </td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/107936/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-recommends-separating-dosing-potassium-lowering-drug-sodium-polystyrene" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue</td> <td>No</td> <td data-order="20170522">May 22, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/105492/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-identifies-no-harmful-effects-date-brain-retention-gadolinium-based" target><span class="text">Transcript</span> </a></span></td> </tr> <tr> <td>FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)</td> <td>No</td> <td data-order="20170516">May 16, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/97983/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA approves label changes for use of general anesthetic and sedation drugs in young children</td> <td>No</td> <td data-order="20170427">April 27, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/104869/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs-young" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women</td> <td>No</td> <td data-order="20170420">April 20, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/104742/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and-tramadol" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder</td> <td>No</td> <td data-order="20170315">March 15, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/103837/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about-increased-risk-serious-pancreatitis-irritable-bowel-drug" target><span class="text">Transcript</span></a></span></td> </tr> <tr> <td>FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate</td> <td>No</td> <td data-order="20170202">February 2, 2017</td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/media/103086/download" target><span class="text">Listen</span></a></span><br> <em>Run Time:<br> 00:3:00</em></td> <td><span contenteditable="false" tabindex="-1"><a class="btn btn-primary" data-widget="btbutton" href="/drugs/drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-about-rare-serious-allergic-reactions-skin-antiseptic" target><span class="text">Transcript</span></a></span></td> </tr> </tbody> </table> </div> <p><a href="http://wayback.archive-it.org/7993/20170111064613/https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm076703.htm" target="_blank">View All Past Podcasts in the FDA Archive</a></p> <h2>Additional Information</h2> <ul> <li><a href="https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drug-safety-podcast/rss.xml">FDA Drug Safety Podcast RSS Feed</a></li> <li><a href="/drugs/drug-safety-and-availability/drug-safety-communications">Drug Safety Communications</a></li> </ul> <h2>More FDA Podcasts</h2> <ul> <li><a href="/drugs/approved-drugs/drug-information-soundcast-clinical-oncology-disco">Drug Information Soundcasts in Clinical Oncology (D.I.S.C.O.)</a></li> <li><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a3eed6fb-2eeb-45fe-b273-8495d3c844bc" href="/drugs/news-events-human-drugs/qa-fda-podcast" title="Q&A with FDA Podcast">Q&A with FDA</a></li> </ul> <br> <br> </div> <aside class="col-md-2 col-md-push-2" role="complementary"> <section id="block-entityviewcontent-4" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> <div class="region region-"> <aside class="lcds-card lcds-card--border-top" > <ul role="menu" class="lcds-description-list"> <li role="menuitem" class="node-current-date lcds-description-list__item"> <div> <h2 class="lcds-description-list__item-heading">Content current as of:</h2> <p class="lcds-description-list__item-text"><time datetime="2024-09-20T00:00:00Z">09/20/2024</time> </p> </div> </li> <li role="menuitem" class="lcds-description-list__item"> <div> <h2 class="lcds-description-list__item-heading">Regulated Product(s)</h2> <ul role="menu" class="lcds-metadata-list"> <li role="menuitem">Drugs</li> </ul> </div> </li> </ul> </aside> </div> </section> </aside> <aside class="col-md-2 col-md-pull-10" role="complementary"> <section id="block-entityviewcontent-3" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> <div class="region region-"> <nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav--side hidden-xs hidden-sm"> <ul class="lcds-section-nav__list lcds-section-nav--side__list"> <li> <a href="/drugs/drug-safety-and-availability/fda-drug-safety-podcasts" class="lcds-section-nav__link lcds-section-nav--side__link lcds-section-nav__parent-link lcds-section-nav--side__parent-link">FDA Drug Safety Podcasts</a> <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_4 js-view-dom-id-d8e65f034db2fc08a3e45542dfea73cf376f994c9c28918b2c1550f45da501db"> </div> </div> <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_1 js-view-dom-id-bf40afb644a0d246320b4b8afdf021b7cfabeea01efc866e97396bc3a048b80d"> </div> </div> </li> </ul> </nav> </div> </section> </aside> </article> </main> </div> </div> <div class="region region-subscribe"> <section id="block-entityviewcontent-5" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix"> </section> </div> <footer class="lcds-footer container-fluid"> <div class="row lcds-footer__primary"> <h2 id="footer-heading" class="sr-only">Footer Links</h2> <nav class="text-center"> <div class="col-sm-4"> <ul class="nav"> <li><a href="/about-fda/about-website/fdagov-archive" >FDA Archive</a></li> <li><a href="/about-fda" >About FDA</a></li> <li><a href="/about-fda/about-website/internet-accessibility" >Accessibility</a></li> </ul> </div> <div class="col-sm-4"> <ul class="nav"> <li><a href="/about-fda/visitor-information" >Visitor Information</a> </li> <li><a href="/about-fda/about-website/website-policies" >Website Policies / Privacy</a></li> <li><a href="/about-fda/jobs-and-training-fda/no-fear-act" >No FEAR Act</a></li> <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure Policy</a></li> </ul> </div> <div class="col-sm-4"> <ul class="nav"> <li><a href="/regulatory-information/freedom-information" title="Freedom of Information Act">FOIA</a></li> <li><a href="https://www.hhs.gov/" title="Health and Human Services" target="_blank">HHS.gov</a></li> <li><a href="https://www.usa.gov/" target="_blank">USA.gov</a></li> </ul> </div> </nav> </div> <div class="row lcds-footer__secondary"> <div class="col-sm-12 col-md-6 col-lg-4 lcds-footer__social-links"> <a href="/about-fda/contact-fda" class="btn btn-default btn-md">Contact FDA</a> <a href="https://www.facebook.com/FDA" title="Follow FDA on Facebook" class="no-disclaimer"> <span class="fa fa-facebook fa-2x" aria-hidden="true"> <span class="sr-only">Follow FDA on Facebook</span> </span> </a> <a href="https://x.com/US_FDA" title="Follow FDA on X" class="no-disclaimer"> <svg class="icon-svg-inline fa-2x" aria-hidden="true"> <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter"> </svg> <span class="sr-only">Follow FDA on X</span> </a> <a href="https://instagram.com/FDA" title="Follow FDA on Instagram" class="no-disclaimer"> <span class="fa fa-instagram fa-2x" aria-hidden="true"> <span class="sr-only">Follow FDA on Instagram</span> </span> </a> <br class='visible-xs-inline'/> <a href="https://www.linkedin.com/company/fda/" title="Follow FDA on LinkedIn" class="no-disclaimer"> <span class="fa fa-linkedin fa-2x" aria-hidden="true"> <span class="sr-only">Follow FDA on LinkedIn</span> </span> </a> <a href="https://youtube.com/@US_FDA" title="View FDA videos on YouTube" class="no-disclaimer"> <span class="fa fa-youtube fa-2x" aria-hidden="true"> <span class="sr-only">View FDA videos on YouTube</span> </span> </a> <a href="/about-fda/contact-fda/subscribe-podcasts-and-news-feeds" title="Subscribe to FDA RSS feeds"> <span class="fa fa-rss fa-2x" aria-hidden="true"> <span class="sr-only">Subscribe to FDA RSS feeds</span> </span> </a> </div> <a href="/" title="FDA Homepage"> <div class="visible-lg-block col-lg-4 text-center lcds-footer__logo"> <span class="sr-only">FDA Homepage</span> </div> </a> <div class="col-sm-12 col-md-6 col-lg-4 text-center lcds-footer__contact-number"> <span class="fa fa-phone" aria-hidden="true"> </span> <span class="sr-only">Contact Number</span> 1-888-INFO-FDA (1-888-463-6332) </div> </div>  </footer> <a href="" id="btn-top" class="btn btn-primary btn-top"><span class="sr-only">Back to </span>Top</a> </div> <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/359990","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"fda_ckeditor_enhancements":{"basePath":"modules\/custom\/fda_ckeditor_enhancements"},"google_analytics":{"account":"G-273DTKB5QW","trackOutbound":true,"trackMailto":true,"trackTel":true,"trackDownload":true,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip"},"bootstrap":{"forms_has_error_value_toggle":1,"modal_animation":1,"modal_backdrop":"true","modal_focus_input":1,"modal_keyboard":1,"modal_select_text":1,"modal_show":1,"modal_size":"","popover_enabled":1,"popover_animation":1,"popover_auto_close":1,"popover_container":"body","popover_content":"","popover_delay":"0","popover_html":0,"popover_placement":"right","popover_selector":"","popover_title":"","popover_trigger":"click"},"ajax":[],"user":{"uid":0,"permissionsHash":"3aef67b4ac7d861d8624bf1f7ab2bc9cfc56d3c25b7d709dc15466dfa996dfb0"}}</script> <script src="/files/js/js_9lof_6HXyxkDc120118GyOuNF6pAPfd8qWfA4s8VzMo.js?scope=footer&delta=0&language=en&theme=preview&include=eJxlT9GOwjAM-6GO3stJ_E2VtVmpaOuqyYHG17OB2IBTpMiyldieUJWuLChspx0fTARiZkeV8qzJi_0mjMyiXOxIwqZ1viS-2pgxUh5E55xq_Ef7npqKGQEV7dRsQ8OFu5kCOX_mkBTdcT1R9Vy4qljyHj0kVKeIawA5oatH2E2X4yGQLjNmlg_69fNdX0Wxj30oCH-Zn_YoLafV-Km535_jG2mmJXSFstgNbVa-023muBcO1D4ibqGHrc8deO2Utg"></script> <script src="/libraries/datatables/media/js/jquery.dataTables.min.js?smjbjq"></script> <script src="/files/js/js_Kgn7Gfixu9Cij2aqLSPPKkV1t0TIACwjRX4Nqc3nnp8.js?scope=footer&delta=2&language=en&theme=preview&include=eJxlT9GOwjAM-6GO3stJ_E2VtVmpaOuqyYHG17OB2IBTpMiyldieUJWuLChspx0fTARiZkeV8qzJi_0mjMyiXOxIwqZ1viS-2pgxUh5E55xq_Ef7npqKGQEV7dRsQ8OFu5kCOX_mkBTdcT1R9Vy4qljyHj0kVKeIawA5oatH2E2X4yGQLjNmlg_69fNdX0Wxj30oCH-Zn_YoLafV-Km535_jG2mmJXSFstgNbVa-023muBcO1D4ibqGHrc8deO2Utg"></script> <script src="/libraries/datatables/extensions/Responsive/js/dataTables.responsive.min.js?smjbjq"></script> <script src="/libraries/datatables/media/js/dataTables.bootstrap4.min.js?smjbjq"></script> <script src="/files/js/js_yRvZK9FXPiajh0GtgATd54O7-xucHKewYOldB6HcH8Y.js?scope=footer&delta=5&language=en&theme=preview&include=eJxlT9GOwjAM-6GO3stJ_E2VtVmpaOuqyYHG17OB2IBTpMiyldieUJWuLChspx0fTARiZkeV8qzJi_0mjMyiXOxIwqZ1viS-2pgxUh5E55xq_Ef7npqKGQEV7dRsQ8OFu5kCOX_mkBTdcT1R9Vy4qljyHj0kVKeIawA5oatH2E2X4yGQLjNmlg_69fNdX0Wxj30oCH-Zn_YoLafV-Km535_jG2mmJXSFstgNbVa-023muBcO1D4ibqGHrc8deO2Utg"></script> <script type="text/javascript" src="/Dc2Go5/dCelR/Sewog/rk5-/5VYNNfD46DcX/DQdKdDY/XS/EsHSMaAwQB"></script></body> </html>